PBMs profit off expensive niche meds

Pharmacy benefits managers are building lucrative side businesses in specialty drugs, becoming in some cases the sole distributors for certain niche medications. Critics say distributing these drugs--whose prices are rising much faster than other meds'--could conflict with the PBMs' primary mission of keeping overall drug prices down for health insurers.

- read the story in the New York Times

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.